{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269506","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.944432+00:00","generated_at":"2026-05-16T23:43:03.803398+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Athira Pharma reports Q3 2025 net loss of $6.6M, cash at $25.2M; exploring strategic alternatives","bullets":["Net loss of $6.6M ($1.68 per share) vs $28.7M ($7.46 split-adjusted) in Q3 2024.","Cash and investments $25.2M as of Sept 30, 2025, down from $51.3M at Dec 31, 2024.","R&D expenses fell to $2.8M from $17.9M; G&A expenses $4.1M vs $7.6M year-over-year.","Company continues to explore strategic alternatives to maximize stockholder value; engaged Cantor Fitzgerald.","Phase 1 data for ALS candidate ATH-1105 showed favorable safety, dose-proportional PK, and CNS penetration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269506","json":"https://secwatch.observer/filing/0001193125-25-269506.json","markdown":"https://secwatch.observer/filing/0001193125-25-269506.md","text":"https://secwatch.observer/filing/0001193125-25-269506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/0001193125-25-269506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:43:03.803398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}